Mannkind reports net loss for second quarter
Mannkind reported $2.16 million in revenues Aug. 7, for a net loss of around $35.3 million for its second quarter, and announced the launch of a clinical trial for its inhalable insulin product Afrezza in partnership with One Drop. Revenues came primarily from the Westlake Village biotech company’s product sales, with $615,000 from collaborations and Read More →
Sienna stock still soaring after $65 million IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Teledyne reports record sales for second quarter
Thousand Oaks-based tech giant Teledyne reported record sales for its second quarter, ended July 2, reaching $671.1 million and net income of $60.1 million, or $1.66 per diluted share. In addition to growth in all its major product lines — particularly its digital imaging segment, which saw an 89.6 percent increase to $188.5 million — Read More →
Amgen stock drops despite strong earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Moorpark company’s medicine bottles target elderly, opioid crisis
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
